Published in Clin Cancer Res on June 25, 2012
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA (2014) 2.48
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A (2013) 1.88
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol (2014) 1.64
Positron emission tomography and functional characterization of a complete PBR/TSPO knockout. Nat Commun (2014) 1.29
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99
Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol (2015) 0.98
Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies. Oncotarget (2014) 0.95
Current and emerging treatment options for uveal melanoma. Clin Ophthalmol (2013) 0.94
The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells. Mol Cancer Ther (2014) 0.91
A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. Ophthalmology (2014) 0.91
Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am (2014) 0.85
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. Oncotarget (2016) 0.85
Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). Int J Oncol (2014) 0.85
Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11. Br J Cancer (2013) 0.83
Combined PKC and MEK inhibition for treating metastatic uveal melanoma. Oncogene (2014) 0.83
Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One (2014) 0.82
Profile of selumetinib and its potential in the treatment of melanoma. Onco Targets Ther (2014) 0.81
Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Res (2015) 0.81
Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway. Oncotarget (2016) 0.79
Melanoma epidemiology, biology and prognosis. EJC Suppl (2013) 0.78
Upcoming translational challenges for uveal melanoma. Br J Cancer (2015) 0.78
Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther (2015) 0.78
GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells. PeerJ (2013) 0.77
Update on Molecular Pathology of Cutaneous Melanocytic Lesions: What is New in Diagnosis and Molecular Testing for Treatment? Front Med (Lausanne) (2014) 0.77
BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells. Oncotarget (2015) 0.77
ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. Cancer Cell (2016) 0.77
RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. Cancer Cell (2017) 0.76
Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol (2017) 0.75
The genetics of uveal melanoma: current insights. Appl Clin Genet (2016) 0.75
WT1 shRNA delivery using transferrin-conjugated PEG liposomes in an in vivo model of melanoma. Exp Ther Med (2016) 0.75
Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot. Case Rep Dermatol (2015) 0.75
Therapeutic interventions to disrupt the protein synthetic machinery in melanoma. Pigment Cell Melanoma Res (2015) 0.75
Uveal Melanoma Cell Lines: Where do they come from? (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc (2016) 0.75
The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma. Oncotarget (2016) 0.75
Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Mol Cancer Ther (2017) 0.75
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res (2009) 4.81
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell (2010) 4.48
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res (2011) 3.36
Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res (2010) 2.90
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res (2007) 2.28
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer (2005) 2.13
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci (2005) 2.00
Regulators of G-protein signaling and their Gα substrates: promises and challenges in their use as drug discovery targets. Pharmacol Rev (2011) 1.98
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med Chem Lett (2010) 1.89
Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res (2008) 1.73
Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res (2003) 1.70
Galphaq expression activates EGFR and induces Akt mediated cardiomyocyte survival: dissociation from Galphaq mediated hypertrophy. J Mol Cell Cardiol (2006) 1.57
Use of data-biased random walks on graphs for the retrieval of context-specific networks from genomic data. PLoS Comput Biol (2010) 1.47
Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res (2011) 1.34
Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest (2003) 1.33
Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci (2003) 1.26
Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res (2012) 1.23
Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. Invest Ophthalmol Vis Sci (2008) 1.18
Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene (2011) 1.16
Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer (2003) 1.16
Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin (2006) 1.15
Immunohistochemical expression of phospho-Akt in uveal melanoma. Melanoma Res (2005) 1.08
Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res (2010) 1.08
The T1799A point mutation is present in posterior uveal melanoma. Br J Cancer (2008) 1.07
Galphaq binds to p110alpha/p85alpha phosphoinositide 3-kinase and displaces Ras. Biochem J (2006) 1.03
c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target? Invest Ophthalmol Vis Sci (2004) 0.95
A simplified method for the culturing of primary adult rat and human hepatocytes as multicellular spheroids. In Vitro Cell Dev Biol (1992) 0.86
Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Arch (2003) 0.84
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Caveolae: from cell biology to animal physiology. Pharmacol Rev (2002) 4.45
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res (2010) 2.90
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 2.75
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res (2002) 2.66
Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet (2011) 2.60
EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell (2009) 2.50
Retracted Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat Med (2010) 2.43
Metastatic tumors of the orbit and ocular adnexa. Curr Opin Ophthalmol (2007) 2.33
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28
Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. J Biol Chem (2002) 2.23
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res (2009) 2.21
miR-34s inhibit osteoblast proliferation and differentiation in the mouse by targeting SATB2. J Cell Biol (2012) 2.15
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res (2012) 1.94
An algorithmic approach to reconstructive surgery and prosthetic rehabilitation after orbital exenteration. Plast Reconstr Surg (2009) 1.93
American Joint Committee on Cancer classification predicts outcome of patients with lacrimal gland adenoid cystic carcinoma. Ophthalmology (2009) 1.92
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res (2012) 1.90
Caveolin, caveolae, and endothelial cell function. Arterioscler Thromb Vasc Biol (2003) 1.90
Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol (2002) 1.86
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res (2013) 1.84
Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res (2011) 1.84
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest (2014) 1.81
RNAa is conserved in mammalian cells. PLoS One (2010) 1.81
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood (2012) 1.74
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res (2012) 1.70
Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev (2012) 1.64
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther (2010) 1.62
Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn (2012) 1.59
LncRNAs expression signatures of renal clear cell carcinoma revealed by microarray. PLoS One (2012) 1.59
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res (2012) 1.55
Conjunctival squamous cell carcinoma in the anophthalmic socket. Ophthal Plast Reconstr Surg (2008) 1.53
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. Am J Pathol (2002) 1.43
c-Jun downregulation by HDAC3-dependent transcriptional repression promotes osmotic stress-induced cell apoptosis. Mol Cell (2007) 1.40
Multidisciplinary management of lacrimal sac/nasolacrimal duct carcinomas. Ophthal Plast Reconstr Surg (2013) 1.40
Efficacy of adjuvant and neoadjuvant therapies for adult orbital sarcomas. Ophthal Plast Reconstr Surg (2010) 1.39
Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A (2013) 1.35
Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood (2005) 1.34
Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol (2003) 1.33
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer (2012) 1.32
Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res (2010) 1.29
Orbital and adnexal sarcoidosis. Arch Ophthalmol (2007) 1.24
Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol Cancer Res (2010) 1.19
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother (2012) 1.18
Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells. PLoS Genet (2013) 1.18
Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res (2013) 1.17
Natural killer/T-cell lymphoma with ocular and adnexal involvement. Ophthalmology (2005) 1.15
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol (2008) 1.14
Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene (2002) 1.14
Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer (2013) 1.14
Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol (2010) 1.13
MEKK1 mediates the ubiquitination and degradation of c-Jun in response to osmotic stress. Mol Cell Biol (2006) 1.12
Trabecular bone score (TBS)--a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J Clin Endocrinol Metab (2013) 1.10
Neoadjuvant chemotherapy-specific and overall treatment outcomes in patients with cutaneous angiosarcoma of the face with periorbital involvement. Head Neck (2008) 1.09
Patterns of regional and distant metastasis in patients with eyelid and periocular squamous cell carcinoma. Ophthalmology (2004) 1.07
Mucinous eccrine adenocarcinoma of the periocular region. Ophthal Plast Reconstr Surg (2006) 1.07
Re: "American Joint Committee on Cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes". Ophthal Plast Reconstr Surg (2013) 1.06
Association of activated c-Met with NRAS-mutated human melanomas. Int J Cancer (2012) 1.06
Sentinel lymph node biopsy for sebaceous cell carcinoma and melanoma of the ocular adnexa. Arch Otolaryngol Head Neck Surg (2007) 1.05
Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy. Autophagy (2012) 1.05
Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition. PLoS One (2011) 1.04
ERS1 encodes a functional homologue of the human lysosomal cystine transporter. FEBS J (2005) 1.03
Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer (2008) 1.03
Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol (2012) 1.03
KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression. Cancer Biol Ther (2010) 1.02
Negative regulation of ISG15 E3 ligase EFP through its autoISGylation. Biochem Biophys Res Commun (2007) 1.02
Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther (2003) 1.02
Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer (2007) 1.01
New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res (2012) 1.01
Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail (2013) 1.01
Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma. Arch Ophthalmol (2007) 0.99
Bariatric surgery results in cortical bone loss. J Clin Endocrinol Metab (2013) 0.98
Superior ophthalmic vein thrombosis in a patient with chronic myeloid leukemia receiving antifibrinolytic and thrombopoietin receptor agonist therapy. J Ocul Pharmacol Ther (2010) 0.98
Sclerosing polycystic adenosis of the lacrimal gland. Ophthalmology (2013) 0.98
Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res (2009) 0.97
Discovery and SAR study of novel dihydroquinoline containing glucocorticoid receptor ligands. Bioorg Med Chem Lett (2005) 0.97
A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res (2012) 0.95
Targeted induction of endogenous NKX3-1 by small activating RNA inhibits prostate tumor growth. Prostate (2013) 0.95
Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa. Curr Opin Ophthalmol (2008) 0.95
Feasibility of preoperative lymphoscintigraphy for identification of sentinel lymph nodes in patients with conjunctival and periocular skin malignancies. Ophthal Plast Reconstr Surg (2003) 0.94
The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1. J Immunother (2012) 0.94
Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study. J Clin Endocrinol Metab (2014) 0.94
Survey of orbital tumors at a comprehensive cancer center in the United States. Head Neck (2010) 0.94
GPNMB expression in uveal melanoma: a potential for targeted therapy. Melanoma Res (2010) 0.94
Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol (2008) 0.94
Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. PLoS One (2010) 0.94
Fibulin-1 is down-regulated through promoter hypermethylation and suppresses renal cell carcinoma progression. J Urol (2013) 0.94
Abnormalities in cortical bone, trabecular plates, and stiffness in postmenopausal women treated with glucocorticoids. J Clin Endocrinol Metab (2014) 0.93
Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. J Biol Chem (2010) 0.93